The life sciences software landscape is undergoing its most significant transformation since the transition from on-premise servers to the cloud. As pharmaceutical giants grapple with the dual pressures of accelerated drug discovery and increasingly complex commercialization strategies, two industry titans—Salesforce and Veeva Systems—are locked in an intensifying arms race to dominate the "agentic" era.
At the recent Veeva Commercial Summit in Boston, the atmosphere was defined by a shift toward autonomous AI. However, Salesforce chose the same window to assert its own progress, revealing that over 140 life sciences organizations, including industry stalwarts such as Novartis, AstraZeneca, Moderna, and Merck Animal Health, have already deployed its Agentforce Life Sciences platform. The conflict represents more than just a battle for market share; it is a fundamental disagreement over how AI should be architected, consumed, and regulated in a high-stakes, compliant environment.
The Dawn of the Agentic Enterprise
The term "agentic AI" refers to systems that do not merely provide information or summarize documents but actively execute tasks, manage workflows, and make autonomous decisions based on pre-set parameters. For the pharmaceutical industry, this shift is critical. From medical science liaisons managing complex research data to sales representatives navigating regulatory boundaries while engaging with physicians, the potential for efficiency gains is massive.
Salesforce’s Agentforce Life Sciences platform is positioned as a horizontal, AI-native layer. Joe Ferraro, SVP and GM of life sciences at Salesforce, emphasizes that the 140 clients currently utilizing the platform are doing so across the entire spectrum of the industry: clinical trials, medical affairs, patient support, and commercial engagement.
For Veeva, the pioneer of the life sciences cloud, this new era is equally existential. CEO Peter Gassner told attendees at the Boston summit that the "Agentic Commercial model changes everything." Veeva is pushing its own vision through its newly announced "Falcon" platform, which aims to bring agentic labor directly into the drug development lifecycle.
A Chronology of Innovation: From Predictive to Autonomous
To understand the current rivalry, one must look at the historical trajectory of both firms. Salesforce’s pivot toward AI is not a recent reaction to the generative AI explosion. The company’s "AI-first" journey began in 2014 when CEO Marc Benioff declared the company’s intent to lead in the intelligence space, followed by the $390 million acquisition of RelateIQ and the launch of Salesforce Einstein in 2016.
For years, Salesforce focused on predictive analytics—forecasting sales and optimizing workflows based on historical data. The shift to "Agentic AI" with the September 2024 launch of Agentforce marked a transition from passive analytics to active digital labor. By the first quarter of fiscal 2027, Salesforce reported that it had processed 28.6 trillion AI tokens—a 152% quarter-over-quarter increase—positioning agentic AI as the company’s largest growth engine since its inception.
Veeva, conversely, has built its reputation on deep, domain-specific vertical integration. While Salesforce is a broad horizontal platform, Veeva has focused on building a "walled garden" for life sciences. In December 2025, Veeva launched its first set of AI agents, including Free Text and Voice agents for its Vault CRM. In March 2026, the company accelerated its capabilities by acquiring Ostro for approximately $100 million, integrating conversational AI designed to handle brand engagement within strict regulatory frameworks.
Data and Architectural Philosophies
The core of the competition rests on two divergent architectural philosophies: Salesforce’s "headless" approach versus Veeva’s "in-context" depth.
The "Headless" Bet
Salesforce is championing the "headless" model. By leveraging the Model Context Protocol (MCP)—an open standard for AI interoperability—Salesforce is essentially "popping the top" off its platform. This allows clients to expose Salesforce’s data models and workflows as API-accessible tools.
"I was with a customer yesterday who has made a significant investment in Anthropic, and they are going to use our MCP service to bring all of those compliant workflows directly inside Claude," says Ferraro. This approach is designed for the modern enterprise that may have already standardized on a specific LLM (Large Language Model) or a specific AI interface, allowing them to plug Salesforce’s compliant, regulated workflows into any environment.
The "In-Context" Depth
Veeva argues that for life sciences, the best AI is the one that stays within the application. Its Vault AI Agents are built to operate exclusively within the Veeva ecosystem. By keeping the model, the data, and the regulatory guardrails in one place, Veeva promises a safer, more integrated experience. Its upcoming "AI Tab," slated for release in August 2026, will provide a conversational layer that queries Vault data within existing security permissions, ensuring that sensitive information never leaves the platform’s governance perimeter.
Addressing the Compliance Conundrum
In an industry governed by the FDA and other global health authorities, "hallucinations"—the tendency of generative AI to make things up—are a dealbreaker. Both companies have centered their strategies on the concept of "determinism."
Salesforce utilizes "Agent Script," a framework that forces the probabilistic AI to adhere to hard-coded, compliant templates. When a rep interacts with a physician, the AI doesn’t have free reign; it must select from a pre-approved set of actions and content. "It cannot go off-script," Ferraro explains, "because those tools are unavailable. They are outside its toolbox."
Veeva employs a similar protective layer. By utilizing Amazon Bedrock for its infrastructure, Veeva standardizes the model layer for its agents, ensuring that while the intelligence is sophisticated, the outputs remain confined to the boundaries of Medical, Legal, and Regulatory (MLR) approved content.
Market Implications and Future Outlook
The shift toward agentic labor is already producing tangible results. Salesforce reports that some smaller clients have reduced their onboarding time to roughly one month, thanks to agents that can automate the configuration of CRM environments—a task that previously required armies of consultants. By using tools like "Claude Code" pointed at the Salesforce platform, a single forward-deployed engineer can now perform the work that previously required a team of ten.
However, the industry remains cautious. As companies like Chiesi and CSL adopt these technologies to unify their commercial and medical operations, the reliance on these automated agents will become a single point of failure if the systems are not managed correctly.
The next twelve months will be telling. Veeva’s Falcon platform, with early-adopter availability in November 2026, will be the true test of whether the industry prefers the deep, application-specific integration of a vertical specialist or the flexible, API-first interoperability of a horizontal giant.
Conclusion
The rivalry between Salesforce and Veeva is a microcosm of the broader AI revolution. It is no longer enough to offer software that manages data; the market now demands software that acts. Whether through Salesforce’s ambitious, open-standard "headless" strategy or Veeva’s highly curated, vertical-specific "in-context" agents, the outcome will fundamentally reshape the pharmaceutical industry.
For life sciences companies, the choice is clear: they must either adapt to the era of agentic labor or risk being left behind in a world where speed, compliance, and autonomous decision-making are the new table stakes. The competition is fierce, the investment is immense, and for the patient, the promise of more efficient clinical trials and more relevant medical information is the ultimate prize.
About the Author
